Troxerutin affects nephropathy signaling events in the kidney of type-1 diabetic male rats

Document Type : Short communication


1 Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

2 Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran

3 Department of Physiology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran


Objective: Nephropathy is known to be the leading cause of kidney failure in diabetic patients. Troxerutin, as a flavonoid component, could provide a novel protective strategy in the prevention of diabetic nephropathy. A large number of reports on the salutary effects of troxerutin inspired us to investigate its effect on the nephropathy signaling events (i.e., expression of TGF-β, miRNA192, and SIP1) in type-1 induced diabetic rats.
Materials and Methods: 50 male Wistar rats were divided into 5 groups including control group, sham group treated with troxerutin for 4 weeks, diabetic group induced by streptozotocin (STZ) injection, DI group including insulin-treated diabetic animals and DT group treated with troxerutin. Ultimately, rat kidneys were extracted, and the level of miR-192 (using qPCR), transforming growth factor-beta (TGF-β), and smad interacting protein 1 (SIP1) using an ELISA kit, was measured.
Results: The level of TGF-β and miRNA192 significantly increased in the diabetic group. However, their expression levels decreased following the administration of troxerutin and insulin (p<0.05) compared to control group. SIP1 was down-regulated in the diabetic group, whereas a spike in the expression levels was observed after troxerutin administration compared to control and troxerutin groups (p<0.05). However, no significant difference was found in the effects of insulin and troxerutin on the level of miR-192, SIP1, and TGF- β.
Conclusion: According to the previous literatures, during the progression of nephropathy, TGF-β represses SIP1 (the repression region in the collagen gene) by increasing the expression of miR-192. Ultimately, in this study, diabetes led to up-regulation of TGF-β while troxerutin proved to have a protective effect on the kidney by increasing SIP and lowering miR-192 levels.


Al‑ Kafaji G, Al‑ Muhtaresh HA. 2018.
Expression of microRNA‑ 377 and
microRNA‑ 192 and their potential as
blood‑ based biomarkers for early detection
of type 2 diabetic nephropathy. Mol Med
Rep, 18: 1171-1180.
Badalzadeh R, Layeghzadeh N, Alihemmati A,
Mohammadi M. 2015. Beneficial effect of
troxerutin on diabetes-induced vascular
damages in rat aorta: histopathological
alterations and antioxidation mechanism. Int
J Endocrinol Metab, 13: e25969.
Braga Gomes K, Fontana Rodrigues K,
Fernandes AP. 2014. The role of
transforming growth factor-beta in diabetic
nephropathy. Int J Med Genet, 28: 2014.
Chang AS, Hathaway CK, Smithies O, Kakoki
M. 2016. Transforming growth factorbeta1 and diabetic nephropathy. Am J
Physiol Renal Physiol, 310: F689-F696.
Chien HY, Chen CY, Chiu YH, Lin YC, Li
WC. 2016. Differential microRNA profiles
predict diabetic nephropathy progression in
Taiwan. Int J Med Sci, 13: 457-465.
Dehnamaki F, Karimi A, Pilevarian AA, Fatemi
I, Hakimizadeh E, Kaeidi A, Allahtavakoli
Troxerutin and nephropathy in type-1 diabetes
AJP, Vol. 12, No. 2, Mar-Apr 2022 115
M, Rahmani MR, Khademalhosseini M,
Bazmandegan G. 2019. Treatment with
troxerutin protects against cisplatin-induced
kidney injury in mice. Acta Chir Belg, 119:
Fan F, Qi J, Liu N, Wang Z, Wang W, Liu H,
Xu X, Chen G, Wang X, Yang H, Johnson
M. 2019. TGF-beta/TGF-beta RII/CLC-3
axis promotes cognitive disorders in
diabetes. Frontiers in bioscience (Landmark
edition), 24: 482-493.
Fan SH, Zhang ZF, Zheng YL, Lu J, Wu DM,
Shan Q, Hu B, Wang YY. 2009. Troxerutin
protects the mouse kidney from d-galactosecaused injury through anti-inflammation
and anti-oxidation. Int Immunopharmacol,
9: 91-96.
Gewin LS. 2020. TGF-β and diabetic
nephropathy: Lessons learned over the past
20 years. Am J Med Sci, 359: 70-72.
Kato M, Zhang J, Wang M, Lanting L, Yuan H,
Rossi JJ, Natarajan R. 2007. MicroRNA192 in diabetic kidney glomeruli and its
function in TGF-β-induced collagen
expression via inhibition of E-box
repressors. Proc Natl Acad Sci USA, 104:
Liu CM, Ma JQ, Lou Y. 2010. Chronic
administration of troxerutin protects mouse
kidney against D-galactose-induced
oxidative DNA damage. Food Chem
Toxicol, 48: 2809-2817.
Müller S, Janke F, Dietz S, Sültmann H. 2020.
Circulating microRNAs as potential
biomarkers for lung cancer. Recent Results
Cancer Res, 215: 299-318.
Østergaard L, Mogensen UM, Bundgaard JS,
Dahl A, Wang A, Torp-Pedersen C,
Gislason G, Køber L, Køber N, Dejgaard
TF, Frandsen CS. 2019. Duration and
complications of diabetes mellitus and the
associated risk of infective endocarditis. Int
J Cardiol, 278: 280-284.
Qadiri A, Bavil FM, Hamidian G, Oskuye ZZ,
Ahmadi M, Oghbaei H, Mehri K, Vatankhah
AM, Keyhanmanesh R. 2019.
Administration of troxerutin improves
testicular function and structure in type-1
diabetic adult rats by reduction of apoptosis.
Avicenna J Phytomed, 9: 374-385.
Pfaffl MW. 2001. A new mathematical model
for relative quantification in real-time RTPCR. Nucleic Acids Res, 29: e45-e45.
Raja B, Saranya D, Prabhu R. 2019. Role of
flavonoid troxerutin on blood pressure,
oxidative stress and regulation of lipid
metabolism. Frontiers in Bioscience (Elite
Ed), 11: 121-129.
Tayel SI, Saleh AA, El-Hefnawy SM,
Elzorkany K, Elgarawany GE, Noreldin RI.
2020. Simultaneous assessment of
microRNAs 126 and 192 in diabetic
nephropathy patients and the relation of
these microRNAs with urinary albumin.
Curr Mol Med, 20: 361-371.
Thomas NS, George K, Selvam AAA. 2019.
Anticancer mechanism of troxerutin via
targeting Nrf2 and NF-κB signalling
pathways in hepatocarcinoma cell line.
Toxicol In Vitro, 54: 317-329.
Tziomalos K, Athyros VG. 2015. Diabetic
nephropathy: new risk factors and
improvements in diagnosis. Rev Diabet
Stud, 12: 110.
Vidyasagar S. Section 5: Acute Complications
of Diabetes. 2019. RSSDI Diabetes,16.
Wojczakowski W, Kobylarek D, Lindner J,
Limphaibool N, Kaczmarek M. 2019.
MicroRNAs–novel biomarkers for
malignant pleural effusions. Contemp Oncol
(Pozn), 23: 133.